European Commission expands Merck Ervebo indication to include children 1 year of age and older
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Commission (EC) has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus.
The EC’s decision follows the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) received on July 20, 2023. The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older. The use of ERVEBO should be in accordance with official recommendations.
“Ebola virus disease is severe and potentially life-threatening for both children and adults. The European Commission’s expanded approval of ERVEBO for children 1 year of age and older is an important milestone for the prevention of disease caused by Zaire ebolavirus,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “When outbreaks of Ebola virus disease occur, they can quickly become a public health crisis. We are proud to play a role, alongside the global public health community, in helping to prepare for potential outbreaks of Zaire ebolavirus.”
In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO to support future Zaire ebolavirus outbreak preparedness and response efforts. To date, over 500,000 doses of the licensed vaccine have been delivered to the stockpile, which is administered by the International Coordinating Group on Vaccine Provision.
Read also: Merck declares topline results from Phase 3 trial of Welirag
Ebola virus disease is a rapidly progressive, severe, potentially fatal and transmissible hemorrhagic illness caused by infection with one of the Ebola virus species. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years. The average fatality rate for Ebola virus disease is approximately 50% but has ranged from 25% to 90% in previous outbreaks.
Human-to-human transmission can occur via blood or bodily fluids, objects (like needles and syringes), possibly from contact with semen from a man who has recovered from Ebola, or direct contact through broken skin or mucous membranes.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd